Cancer Drug Study Ignites Biotech Shares Days After Goldman Cut
(Bloomberg) -- Immunomedics Inc. shares more than doubled after a study of its breast cancer drug was stopped early on promising results.
The biotech company surged as much as 115% to $20.20 on Monday after analysts said the results boded well for the drug's potential approval to treat patients with triple negative breast cancer, an aggressive form of the disease. The news came just days after a Goldman Sachs analyst downgraded the shares on quality-control issues at a manufacturing site.
Immunomedics's drug, sacituzumab govitecan, has endured a rocky development path. The drug failed to secure accelerated approval from U.S. regulators in January 2019. The stock had fallen 56% this year through Friday's close ahead of an expected new regulatory decision date on June 2.
Wells Fargo analyst Jim Birchenough upgraded the stock to overweight from equal-weight on Monday, saying he anticipates the drug will ultimately become a standard of care for relapsed/refractory triple negative breast cancer. He cautioned, however, that quality-control issues remain a risk to securing Food and Drug Administration approval.
©2020 Bloomberg L.P.
-
Extracting Value From Battery Scrap Could Be Challenging For India | The Reason Why
A discarded lithium-ion battery still contains valuable materials such as lithium, nickel and cobalt. These can be recovered and reused. When such batteries are crushed and shredded, they produce a dark powder called black mass.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.